![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Compromising between European and US allergen immunotherapy schools: Discussions from GUIMIT, the Mexican immunotherapy guidelines
Larenas Linnemann, Désirée y Rodríguez Pérez, Noel y Luna Pech, Jorge A. y Rodríguez González, Mónica y Blandón Vijil, María Virginia y Del Río Navarro, Blanca E. y Costa Domínguez, María del Carmen y Navarrete Rodríguez, Elsy Maureen y Macouzet Sánchez, Carlos y Ortega Martell, José Antonio y Pozo Beltrán, César Fireth y Estrada Cardona, Alan y Arias Cruz, Alfredo y Rodríguez Galván, Karen Guadalupe y Brito Díaz, Herson y Canseco Raymundo, María Del Rosario y Castelán Chávez, Enrique Emanuel y Escalante Domínguez, Alberto José y Gálvez Romero, José Luis y Gómez Vera, Javier y González Díaz, Sandra Nora y Guerrero Núñez, María Gracia Belinda y Hernández Colín, Dante Daniel y Macías Weinmann, Alejandra y Mendoza Hernández, David Alejandro y Meneses Sánchez, Néstor Alejandro y Mogica Martínez, María Dolores y Moncayo Coello, Carol Vivian y Montiel Herrera, Juan Manuel y O'Farril Romanillos, Patricia María y Onuma Takane, Ernesto y Ortega Cisneros, Margarita y Rangel Garza, Lorena y Stone Aguilar, Héctor y Torres Lozano, Carlos y Venegas Montoya, Edna y Wakida Kusunoki, Guillermo y Partida Gaytán, Armando y López García, Aída Inés y Macías Robles, Ana Paola y Ambriz Moreno, María de Jesús y Azamar Jácome, Amyra Ali y Beltrán de Paz, Claudia Yusdivia y Caballero López, Chrystopherson y Fernández de Córdova Aguirre, Juan Carlos y Fernández Soto, José Roberto y Lozano Sáenz, José Santos y Oyoqui Flores, José Joel y Osorio Escamilla, Roberto Efrain y Ramírez Jiménez, Fernando y Rivero Yeverino, Daniela y Martínez Infante, Eric y Medina Ávalos, Miguel Alejandro (2020) Compromising between European and US allergen immunotherapy schools: Discussions from GUIMIT, the Mexican immunotherapy guidelines. World Allergy Organization Journal, 13 (8). p. 100444. ISSN 1939-4551
|
Texto
1-s2.0-S1939455120303471-main.pdf - Versión Publicada Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (367kB) | Vista previa |
Resumen
Background: Allergen immunotherapy (AIT) has a longstanding history and still remains the only disease-changing treatment for allergic rhinitis and asthma. Over the years 2 different schools have developed their strategies: the United States (US) and the European. Allergen extracts available in these regions are adapted to local practice. In other parts of the world, extracts from both regions and local ones are commercialized, as in Mexico. Here, local experts developed a national AIT guideline (GUIMIT 2019) searching for compromises between both schools. Methods: Using ADAPTE methodology for transculturizing guidelines and AGREE-II for evaluating guideline quality, GUIMIT selected 3 high-quality Main Reference Guidelines (MRGs): the European Academy of Allergy, Asthma and Immunology (EAACI) guideines, the S2k guideline of various German-speaking medical societies (2014), and the US Practice Parameters on Allergen Immunotherapy 2011. We formulated clinical questions and based responses on the fused evidence available in the MRGs, combined with local possibilities, patient's preference, and costs. We came across several issues on which the MRGs disagreed. These are presented here along with arguments of GUIMIT members to resolve them. GUIMIT (for a complete English version, see Supplementary data) concluded the following: Results: Related to the diagnosis of IgE-mediated respiratory allergy, apart from skin prick testing complementary tests (challenges, in vitro testing and molecular such as species-specific allergens) might be useful in selected cases to inform AIT composition. AIT is indicated in allergic rhinitis and suggested in allergic asthma (once controlled) and IgE-mediated atopic dermatitis. Concerning the correct subcutaneous AIT dose for compounding vials according to the US school: dosing tables and formula are given; up to 4 non-related allergens can be mixed, refraining from mixing high with low protease extracts. When using European extracts: the manufacturer's indications should be followed; in multi-allergic patients 2 simultaneous injections can be given (100% consensus); mixing is discouraged. In Mexico only allergoid tablets are available; based on doses used in all sublingual immunotherapy (SLIT) publications referenced in MRGs, GUIMIT suggests a probable effective dose related to subcutaneous immunotherapy (SCIT) might be: 50–200% of the monthly SCIT dose given daily, maximum mixing 4 allergens. Also, a table with practical suggestions on non-evidence-existing issues, developed with a simplified Delphi method, is added. Finally, dissemination and implementation of guidelines is briefly discussed, explaining how we used online tools for this in Mexico. Conclusions: Countries where European and American AIT extracts are available should adjust AIT according to which school is followed.
| Tipo de elemento: | Article | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Materias: | R Medicina > RC Medicina Interna, Psiquiatría, Neurología | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Divisiones: | Medicina | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Usuario depositante: | Editor Repositorio | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Creadores: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fecha del depósito: | 15 Oct 2020 12:43 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Última modificación: | 14 Mar 2022 21:53 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| URI: | http://eprints.uanl.mx/id/eprint/20100 |
orcid.org/0000-0002-5713-5331Actions (login required)
 |
Ver elemento |
Descargar estadísticas
Descargar estadísticas
